A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer

The combination of drugs targeting Ral and PI3K/AKT signaling has antitumor efficacy in preclinical models of pancreatic cancer. We combined dinaciclib (small molecule cyclin dependent kinase inhibitor with MK‐2206 (Akt inhibitor) in patients with previously treated/metastatic pancreatic cancer. Pat...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Transl Sci
Glavni autori: Murphy, Adrian G., Zahurak, Marianna, Shah, Mirat, Weekes, Colin D., Hansen, Aaron, Siu, Lillian L., Spreafico, Anna, LoConte, Noelle, Anders, Nicole M., Miles, Tearra, Rudek, Michelle A., Doyle, L. Austin, Nelkin, Barry, Maitra, Anirban, Azad, Nilofer S.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7719383/
https://ncbi.nlm.nih.gov/pubmed/32738099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12802
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items